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Abstract We respond to comments byDufrost et al. about the
RAPS trial, in particular, showing that the trial did achieve its
target sample size; pointing out that thrombin potential is not
synonymous with overall thrombin generation; confirming
that overall, no increased thrombotic risk was evident com-
paring rivaroxaban with warfarin; and that high-risk patients
(28% were triple positive, representative of patients with
venous thromboembolism requiring standard-intensity
anticoagulation) were included; and clarifying our rationale
for using a laboratory surrogate primary outcome measure
instead of a clinical one.
Keywords Antiphospholipid syndrome . Venous
thromboembolism . Rivaroxaban .Warfarin . Thrombin
generation
Commentary
We write to correct some inaccurate statements about the
rivaroxaban in antiphospholipid syndrome (RAPS) trial in
Dufrost et al.’s review [1, 2].
They indicate that the RAPS trial did not achieve the target
sample size. The RAPS trial paper stated that 58 patients per
group would need to be enrolled to ensure with 80% power that
a two-sided 95% CI would exclude the non-inferiority thresh-
old, assuming a common SD of 36%, one-sided significance
level of 2.5% and 12% of patients who were not assessable for
the primary outcome. It follows that the 54 and 56 patients
analysed (i.e. which excluded 6 patients [5.2% of the total
116 recruited] who were not assessable), for the primary out-
come measure in the rivaroxaban and warfarin groups, respec-
tively, were sufficient to achieve the planned statistical power.
Second, Dufrost et al. stated “Overall, patients treated with
rivaroxaban had a significant twofold-increased thrombin po-
tential, suggesting a higher thrombotic risk. However, authors
stated that no increased thrombotic risk was noticed in the
rivaroxaban arm compared to standard-intensity warfarin be-
cause no clinical event occurred during the short follow-up
(210 days).” The RAPS paper stated that when anticoagulation
intensity was assessed by percentage change in ETP alone,
rivaroxaban was inferior to warfarin in patients with
antiphospholipid syndrome (APS) and previous venous throm-
boembolism. However, peak thrombin generation was lower
with rivaroxaban and, therefore, the overall thrombogram indi-
cated no difference in thrombotic risk. This conclusion is sup-
ported by in vivo coagulation activation marker concentrations
This comment refers to the article available at http://dx.doi.org/10.1007/
s11926-016-0623-7
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being raised in only a few patients in both treatment groups.
Additionally, no new thrombotic events were seen during
6 months of treatment.
The RAPS trial paper explained with regard to interpreta-
tion of the overall thrombogram: “Warfarin, therefore, affects
all phases of thrombin generation equally, whereas rivaroxaban
mainly affects the initiation and propagation of thrombin gen-
eration, leading to a delay in formation of the prothrombinase
complex. As a result, the thrombin generation curve becomes
protracted, which in turn lengthens the lag time and time to
peak thrombin generation, and leads to greater ETP thanwould
be expected for the degree of anticoagulation.” Our conclu-
sions from the RAPS trial are supported by the independent
expert comment [3], which stated “The endogenous thrombin
potential (the parameter most frequently reported in the litera-
ture for calibrated automated thrombography), indicated infe-
riority of rivaroxaban. By contrast, peak thrombin concentra-
tions, which Cohen and colleagues argue more accurately re-
flects thrombotic risk than endogenous thrombin potential,
suggested non-inferiority, supporting their conclusion of non-
inferiority of rivaroxaban.”
Further, Dufrost et al. imply that thrombin potential (cor-
rectly termed endogenous thrombin potential) is synonymous
with overall thrombin generation. It is not. The thrombin gen-
eration curve (or thrombogram) is quantified in terms of the
lag time, time to peak thrombin generation, peak thrombin
generation, and endogenous thrombin potential (ETP), which
is the area under the curve.
We explained our rationale for using a laboratory surrogate
outcome measure as follows: “Rather, the trial was designed
with a laboratory surrogate outcome measure to assess the
mechanism of action of the interventions in these patients. A
trial with a primary endpoint of recurrent thrombosis would
require a sample of several thousand patients, which is unfea-
sible for patients with thrombotic APS, and a much longer
follow-up period.”
Third, Dufrost et al. stated “Indeed, high-risk APS patients
were not included” and “a low percentage of patients with
triple positivity were included (25%).” The RAPS paper stated
“28% of patients in RAPS had triple positivity.” We also stat-
ed “The RAPS trial had an intended selection bias because we
excluded patients who had had venous thromboembolism
(VTE) and developed recurrent events while taking
standard-intensity anticoagulation (i.e. needing higher-
intensity anticoagulation) and those with arterial events.”
The proportion of triple positive patients included in RAPS
is representative of VTE patients requiring standard-intensity
anticoagulation in our APS population and consistent with the
proportion in APS patients suggested in a large multicentre
study [4].
In conclusion, we believe that the concerns raised by
Dufrost et al. [2] are unfounded.
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